Overview of Aurizon (+ANTIBACTERIAL)

Property	Description
Active Ingredients	Marbofloxacin, Clotrimazole, Dexamethasone
Form	Topical Oily Suspension (Ear Drops)
Pharmacological Class	Combined Antimicrobial, Antifungal, and Anti-inflammatory Agent
General Purpose	Addresses mixed infection and inflammation in the ear
Origin	Synthetic

Aurizon is a veterinary medicinal product defined as a fixed-dose combination drug for the canine species, formulated to address complex ear pathologies. This medication falls into the broad pharmacological class of a combined antimicrobial, antifungal, and anti-inflammatory agent, designed for topical otic application. Its synthesis and strategic component selection ensure a comprehensive action against the three primary factors involved in acute otitis externa: bacteria, fungi, and accompanying tissue inflammation.

What is the Pharmacological Classification of Aurizon?

Aurizon is primarily classified as a triple-component veterinary medicine for local treatment, intended for use in dogs. The active component Marbofloxacin is classified as a synthetic third-generation fluoroquinolone, a class recognized for its broad-spectrum bactericidal activity against susceptible organisms. The combination distinguishes itself by using a potent glucocorticoid, Dexamethasone, alongside two specific antimicrobial agents, an approach frequently selected when significant inflammatory swelling and pain are present.

Composition: Marbofloxacin, Clotrimazole, and Dexamethasone

The preparation contains three distinct, synthetic active ingredients by their International Nonproprietary Name (INN): the fluoroquinolone antibiotic Marbofloxacin, the imidazole antifungal Clotrimazole, and the potent glucocorticoid anti-inflammatory Dexamethasone. Combination preparations are utilized for tackling polymicrobial infections. The medication is presented as an oily suspension ear drop, ensuring necessary topical delivery and prolonged contact of the active components within the ear canal.

General Purpose of this Triple-Component Suspension

The general purpose of this specific three-part suspension is to offer a comprehensive, broad-spectrum approach to managing the key components of ear issues in dogs. This is achieved through the synergistic actions that target microbial growth while providing essential anti-pruritic and anti-exudative relief from inflammation. The strategic inclusion of a potent anti-inflammatory agent alongside the antimicrobial components is crucial for mitigating the pain and swelling associated with infections, thereby addressing the clinical signs of the underlying condition.

What side effects are possible with Aurizon (+ANTIBACTERIAL)?

Possible Side Effects and Safety Information

Official regulatory documentation structures the safety profile of this medicine based on frequency classifications, affected organ systems, and defined restrictions for use.

Adverse Reactions Classified by Frequency

Adverse reactions are classified according to their rate of occurrence as documented in regulatory texts. Deafness, or partial hearing loss, is classified as a rare adverse reaction. Localized skin reactions, such as transient redness and inflammation at the application site, have also been observed. Reactions such as elevated serum alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), along with skin thinning, are considered very rare. The occurrence of delayed healing or adrenal gland suppression (hypoadrenocorticism) is of undetermined frequency.

Classification	Example Adverse Reactions (SOC)
Rare	Deafness (Ear and Labyrinth Disorders)
Very Rare	Elevated Liver Enzymes (Investigations)

Contextual Safety Patterns

Specific systemic effects are associated with the duration of exposure. Effects such as skin thinning and hypoadrenocorticism are known adverse reactions linked to the prolonged and intensive use of topical corticosteroids. Conversely, instances of deafness are often noted to be of a transient nature and have been observed mainly in elderly subjects. The safety information notes that changes in biochemical parameters will typically reverse once treatment has stopped.

Safety-Related Restrictions

Regulatory documents include high-level constraints and contraindications. The medicine is contraindicated if a perforation of the tympanic membrane is present. It is also restricted in subjects with known hypersensitivity to marbofloxacin, clotrimazole, dexamethasone, or related drug classes. General cautions for the fluoroquinolone class note risks of arthropathies in immature subjects.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented manifestations and required actions for an overdose of Aurizon (Marbofloxacin, Clotrimazole, Dexamethasone topical oily suspension), based strictly on government regulatory documentation.

Overdose studies involving the topical product reveal a limited risk profile, reflecting its intended use.

Documented Manifestations and Outcomes

Feature	Official Regulatory Statement
Documented Sign	Transient salivation (observed at 3–5 times the recommended dose).
Serious Outcomes	No serious systemic adverse effects were recorded in overdose studies.

Required Emergency Actions

In the event of suspected or observed overdose, official guidance mandates a procedural response focused on discontinuing the medicine and managing any mild signs. This is due to the non-serious nature of the documented effects.

Feature	Official Regulatory Statement
Immediate Action	Discontinuation of treatment.
Supportive Measure	Symptomatic treatment should be applied.
Antidote Status	No specific antidote is documented in the official prescribing information.

Urgent veterinary medical attention is not explicitly required for the mild, transient signs described in the regulatory profile. The required actions center on management and observation.

Therapeutic Uses of Aurizon (+ANTIBACTERIAL)

Quick Facts: Aurizon (+ANTIBACTERIAL) Uses

Targeted Condition: Otitis externa
Associated Pathogens: Bacteria sensitive to marbofloxacin and fungi, specifically Malassezia pachydermatis, sensitive to clotrimazole
Species: Dogs

Therapeutic Overview of Aurizon (+ANTIBACTERIAL)

Aurizon is indicated for managing canine otitis externa. This is a common inflammation of the external ear canal in dogs. The product is formulated to address both the microbial component and the associated inflammatory response.

The therapeutic action of this combination preparation specifically targets microbial organisms frequently involved in the condition. It is used against bacteria, including Staphylococcus species and Pseudomonas aeruginosa, that are susceptible to marbofloxacin, which provides an antibacterial effect. Additionally, the formulation contains clotrimazole, an agent that addresses fungal proliferation, particularly against the common yeast Malassezia pachydermatis.

By treating the underlying bacterial and fungal causes of the infection, and by including an anti-inflammatory component, the preparation helps to resolve the clinical signs of the ear condition, which can include discomfort and discharge. Treatment protocols should be determined by a veterinary professional, ideally following identification of the susceptible pathogens via sensitivity testing.

Regulatory References

EMA therapeutic overview

Eligibility and Restrictions for Use

Who can and cannot use Aurizon (+ANTIBACTERIAL)?

The eligibility for Aurizon, a veterinary ear preparation, is strictly defined by regulatory authorities for the target species, dogs. Official labeling establishes clear groups who are eligible and those who are formally contraindicated.

Eligibility Scope	Status Defined by Official Documents
Target Species	Dogs (adults only, with conditions)
Age-Related Rule	Contraindicated in puppies less than 4 months of age
Hypersensitivity	Contraindicated in dogs with a known allergy to any active ingredient
Eardrum Integrity	Contraindicated in dogs suffering from perforation of the tympanic membrane
Reproductive Status	Not recommended during pregnancy or lactation

Eligibility Classification

The regulatory status designates several groups as contraindicated, meaning they must not use the medicine due to established safety concerns. This includes dogs with compromised eardrums or known component hypersensitivity. Furthermore, the fluoroquinolone component (Marbofloxacin) makes the product contraindicated for use in young puppies under four months old. Use in all eligible adult dogs is conditional, primarily requiring that the infectious organisms have been confirmed as susceptible to the active components.

What should I know about interactions with other medicines?

The regulatory interaction profile for Aurizon ear drops, suspension (Marbofloxacin, Clotrimazole, Dexamethasone) is defined strictly by the official prescribing information detailed in government health authority documents, such as the Summary of Product Characteristics (SmPC). This section addresses officially documented interaction patterns only.

Official Interaction Status

The authoritative regulatory label for this specific finished product consistently reports that there are no known interactions with other medicinal products or other forms of interaction when Aurizon is used as prescribed. This finding is based on the data assessed for this topical formulation.

Interaction Category	Official Regulatory Statement
Drug–Drug Combinations	None known. No specific drug combinations are officially prohibited due to an interaction risk.
Pharmacokinetic Interactions	None known. No official documentation exists for interactions involving metabolic enzymes (e.g., CYP) or drug transporter systems.
Pharmacodynamic Interactions	None known. The label does not report additive or synergistic effects when co-administered with other substances.
Food, Alcohol, Supplements	None documented. No interaction with food, alcohol, or herbal products is formally stated.
Administration Timing Rules	None mandated. The official labeling does not require separation of administration times with other products.

This complete absence of documented interactions dictates the product's official interaction structure. According to the regulatory data, this topical medicine is not associated with specific constraints, prohibitions, or required timing rules concerning the co-administration of other substances. The profile confirms the product’s interaction profile is characterized by this explicit "None known" status.

Mechanism of Action

Targeted Disruption of Pathogen DNA and Cell Structure

The antibacterial component, Marbofloxacin, acts by inhibiting the essential bacterial enzymes DNA Gyrase and Topoisomerase IV, trapping the DNA in a fragmented state and leading directly to bactericidal cell death, thereby reducing the pathogenic microbial population. Simultaneously, the antifungal component, Clotrimazole, interferes with the fungal enzyme 14-alpha demethylase, preventing the synthesis of ergosterol, which is critical for fungal cell membrane integrity, leading to fungistatic or fungicidal action. These distinct molecular mechanisms contribute to the targeted clearance of both bacterial and fungal pathogens.

Upstream Suppression of Inflammatory Signaling

The anti-inflammatory component, Dexamethasone, operates by binding to Glucocorticoid Receptors and triggering the synthesis of Annexin-A1, which effectively inhibits the PLA2 enzyme. This upstream blockade halts the entire Arachidonic Acid Cascade, preventing the formation of powerful inflammatory mediators like Prostaglandins and Leukotrienes. The resulting physiological effect is the suppression of local tissue swelling, fluid exudate, and nociceptive signaling.

Mechanistic Synergy and Local Efficacy

The combination of these three agents influences physiological processes by concurrently targeting the microbial factors and the host tissue inflammatory response. Dexamethasone’s anti-edema action reduces swelling and fluid build-up, which, in turn, enhances the local penetration and effective concentration of both Marbofloxacin and Clotrimazole, which supports the local concentration of the antimicrobial agents.

Dosage and Administration Information

Instruction Map: How to use Aurizon (+ANTIBACTERIAL) — Official Administration Guidelines

This map details the established administration protocol for Aurizon.

Administration Scope

Feature	Official Guideline
Route of administration	Auricular use (topical application to the ear canal) only.
Dosing schedule	10 drops applied to the affected ear(s). Each drop contains a specific, fixed amount of Marbofloxacin, Clotrimazole, and Dexamethasone acetate.
Timing in relation to meals (if applicable)	Not applicable; topical administration.
Preparation requirements (if applicable)	The bottle must be shaken well before each use to ensure the oily suspension is homogeneous.
Age-group administration rules	Authorized exclusively for the canine species. No weight or age-specific dosage adjustments for dogs are detailed in the standard regimen.
Missed-dose rules	Not explicitly detailed. Administration is intended to be once daily.
Special procedural conditions	The external ear canal must be meticulously cleaned and dried prior to initial treatment.

Instruction Classifications (High-Level)

Classification	Official Pattern
Administration method type	Topical (Otic).
Frequency pattern	Once daily.
Protocol basis	Standardized veterinary application instructions.
Use-context constraints	Strictly confined to veterinary use in dogs; application requires a clean, dry ear canal and a maximum duration limit.

Resulting Procedural Structure

Official step sequence:

Meticulously clean and dry the external ear canal.
Shake the bottle well before use.
Apply 10 drops of the suspension to the affected ear(s).
Massage the base of the ear briefly and gently to distribute the suspension.
Administer once daily for a course duration of 7 days, with potential extension up to 14 days following veterinary re-evaluation.

Connection to the overall use protocol (2–4 sentences): The established protocol defines a standardized, non-systemic use model that mandates a fixed daily dose of 10 drops applied to the ear canal. This structure requires specific preparation steps to ensure adequate contact of the suspension and defines a time-limited course of 7 to 14 days. These instructions collectively define the non-systemic administration model for this triple-component veterinary medicine.

Recent Clinical Evidence

Overview of Studies for Aurizon (+ANTIBACTERIAL)

This section provides an overview of the clinical research and evidence base for the use of Aurizon, focusing on the design and scope of studies as reported in regulatory documents and peer-reviewed scientific sources. The evidence base for this combination ear drop primarily consists of high-quality Randomized Comparative Field Studies (Clinical Trials) that were conducted to explore the product's intended uses.

Evidence for Use in Canine Otitis Externa

The primary research for Aurizon was evaluated in dogs (canine species) presenting with the common ear condition known as otitis externa. The studies were designed to evaluate the Marbofloxacin, Clotrimazole, and Dexamethasone components as a combined formulation.

Research examined dogs diagnosed with otitis externa where the condition was associated with microorganisms known to be susceptible to the active ingredients, such as certain strains of Staphylococcus bacteria and the yeast Malassezia pachydermatis. These studies monitored subjects over defined time intervals as part of research exploring short-term symptom changes and microbial patterns.

The field studies reported measurements of how outcomes related to physical discomfort, such as pain, redness, and discharge, were measured during the defined time intervals. Researchers also reported data on the status of the target bacteria and yeast, assessing the microbial environment within the ear canal.

Long-Term Research and Durability of Outcomes

The evidence is derived from settings with varying symptom burdens, and follow-up durations were limited in the primary regulatory studies. Studies typically monitored the dogs through the treatment course and assessed the outcome in the intermediate term, often around 14 to 21 days after the start of treatment. However, long-term effects are not fully established by the existing regulatory research. Evidence regarding how symptoms evolved over extended periods after the trials concluded is still emerging.

What is Still Uncertain About the Research Evidence

The available evidence contributes to the broader evidence landscape but also highlights what is still uncertain about the combination ear drop. Evidence quality varies across studies, and the findings were mixed when comparing the product against different available treatments. A research limitation is that comparative evidence is lacking regarding many other available combination treatments. Furthermore, findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References Aurizon Ear Drops, Suspension for Dogs - Summary of Product Characteristics (SPC)

Frequently Asked Questions (FAQ)

Common questions about Aurizon (+ANTIBACTERIAL) (FAQ)

Q: How long does it typically take to notice the effects of Aurizon?

Studies and official documents describe the anti-inflammatory component, Dexamethasone, as a potent agent intended to address symptoms quickly. Its mechanism contributes to the rapid suppression of local swelling, pain, and redness, which are key symptoms of the underlying condition. The overall effect relies on this combined action with the antimicrobial components.

Q: Is it normal to feel a mild burning sensation when starting Aurizon?

Official regulatory documents have reported localized skin reactions at the application site, such as transient redness and inflammation, but these are noted to occur on rare occasions. These individual responses are part of the overall clinical picture, and any discomfort is noted by the official documentation.

Q: Can Aurizon cause dizziness or drowsiness?

The official product information includes a caution about the fluoroquinolone antibiotic component, Marbofloxacin. In rare instances, this class of antibiotics has been associated with convulsive seizures in animals already suffering from central nervous system disorders.

Q: Can I take over-the-counter pain relievers while using Aurizon?

According to the official product label, there are no known interactions with other medicinal products when this specific topical formulation is used as prescribed. The regulatory profile does not list any prohibitions on co-administering other medicines.

Q: Does Aurizon interact with any vitamins or supplements?

Official regulatory texts report no documented interactions between this topical medicine and food, alcohol, or herbal products/supplements. The interaction profile is characterized by this explicit 'none known' status.

Q: Is Aurizon safe to use if I have kidney problems?

The official safety profile notes that changes in certain blood parameters, which may relate to the function of organs like the liver or kidneys, have been observed in studies. Official information indicates these changes were observed to typically reverse once the treatment was stopped.

Q: Can Aurizon affect blood sugar levels?

The anti-inflammatory component, Dexamethasone, belongs to a class of medicines known as corticosteroids, which can have systemic effects. Due to these metabolic actions, corticosteroids may cause changes in biochemical parameters, including those related to blood sugar regulation.

Q: Why is it important to complete the full course of Aurizon?

Regulatory guidance emphasizes that the reliance on a single class of antibiotics, such as the fluoroquinolone component in this medicine, carries a risk. This practice may contribute to the development of bacterial resistance, and the full course duration is established by regulatory documents to mitigate this risk.

Q: What happens if I stop using Aurizon too soon?

Stopping any course of treatment with an antibiotic component prematurely risks the development of microbial resistance in the target organisms. It may also lead to the original infection not being fully cleared, resulting in a potential recurrence of symptoms.

Q: What happens if I accidentally use too much Aurizon?

Studies examining over-exposure found that use at three times the recommended amount led to observed changes in biochemical parameters. Regulatory information confirms that these changes were seen to reverse once the administration of the product was stopped.

Q: Does Aurizon affect how other medicines work in the body?

The official product label reports that there are no known interactions with other medicinal products when this topical formulation is used as prescribed. The interaction profile is not associated with specific constraints regarding the co-administration of other substances.

Q: What is the risk of an allergic reaction to Aurizon?

The product is formally contraindicated for any subject with a known hypersensitivity or allergy to any of its three active components or related drug classes. Localized skin reactions at the application site are reported on a rare basis.

Q: What should I do if I miss a dose of Aurizon?

The regulatory protocol establishes a standardized, once-daily application schedule. This schedule defines the fixed pattern for the product's administration, and no specific instruction is provided for missed doses in the core regulatory documents.

Q: Where can I find the official regulatory information for Aurizon?

The full set of regulatory documents, such as the Summary of Product Characteristics (SmPC) or the approved Patient Information Leaflet, are published and available on the websites of government health agencies that authorized the medicine.

Q: What type of conditions require the combination of ingredients found in Aurizon?

The medicine is indicated for conditions where the infection is polymicrobial—that is, caused by both bacteria and fungi. Specifically, the product is used when the organisms involved are confirmed as sensitive to Marbofloxacin and Clotrimazole, along with associated inflammation.

Q: Do people typically experience withdrawal effects after stopping Aurizon?

Systemic effects, such as the suppression of adrenal gland function, are listed in official safety information as adverse reactions associated with the prolonged and intensive use of topical corticosteroids. The frequency of this effect is described as undetermined.

Q: Are there different versions of Aurizon approved in different countries?

Aurizon is a specific, fixed-dose combination of Marbofloxacin, Clotrimazole, and Dexamethasone. This name and specific composition are approved by various government health authorities around the world for veterinary use in dogs.

Q: Can Aurizon cause changes in mood or behavior?

Official regulatory cautions note that the fluoroquinolone antibiotic class has been associated with convulsive seizures in rare instances in animals with existing central nervous system conditions. The official cautions primarily focus on this link.

Q: Is the evidence for Aurizon based on human or animal studies?

Aurizon is strictly designated as a veterinary medicinal product. Accordingly, all of the primary research evidence and clinical studies supporting its authorization are based on its intended target species: dogs.

Q: Is Aurizon ever used as a preventative measure?

According to the regulatory documents defining its scope, Aurizon is indicated for the treatment of specified ear conditions. It is not described or authorized in the regulatory label as a preventative measure.

Q: Is it mandatory to inform my doctor about all current medications before starting Aurizon?

Regulatory guidance emphasizes the need for veterinary professional oversight before application. This includes having the eardrum verified and the full clinical context evaluated. This evaluation is necessary to assess the full clinical context.

Q: Does Aurizon come with a patient leaflet?

As a regulated medicinal product, the manufacturer is officially required by health authorities to provide a Package Leaflet (or Patient Information Leaflet). This document contains the full set of administration instructions, warnings, and safety information.

How should Aurizon (+ANTIBACTERIAL) be stored and disposed of?

Storage and Disposal Instructions for Aurizon

Official regulatory guidelines dictate specific conditions for storing and disposing of Aurizon ear drops, suspension.

Storage Requirements

The product must not be stored above 30, C and must be protected from light. It is prohibited to freeze the product. For child safety, the medicine must be stored out of the sight and reach of children.

Stability and Shelf-Life

While the unopened product has a shelf-life of 2 years, the stability is reduced once the container is opened. The shelf-life after first opening the immediate packaging is 2 months.

Disposal Protocol

Unused or expired Aurizon must not be disposed of via wastewater or regular household waste. Disposal must adhere to local requirements and utilize approved take-back schemes or national collection systems for veterinary medicinal products.

Aurizon (+ANTIBACTERIAL)